文献速递泌尿生殖与妇科肿瘤放疗

ASCENDE-RT:比较低剂量率近距离放疗推量与剂量递增外照射推量治疗中高危前列腺癌的随机试验健康相关生活质量分析

ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-02-21

该多中心随机试验纳入357例中高危前列腺癌患者,1:1随机接受剂量递增外照射推量(DE-EBRT,n=177)或低剂量率前列腺近距离放疗推量(LDR-PB,n=180)作为联合治疗的一部分。采用SF36v2问卷评估健康相关生活质量(HR-QoL),中位随访6年。结果显示,两组在11个量表中有9个的平均评分与基线相比无显著差异;两组在角色生理和性功能量表均出现临床显著下降;LDR-PB组在生理功能和泌尿功能量表上的平均评分下降显著大于DE-EBRT组。

要点

  • 中位随访6年,两组11个HR-QoL量表中有9个平均评分较基线无显著差异。
  • 两组角色生理和性功能量表均出现临床显著下降(平均评分下降≥10)。
  • LDR-PB组生理功能和泌尿功能评分下降显著大于DE-EBRT组。

核心结论

  • 中位随访6年时,两组在11个HR-QoL量表中有9个的平均评分与基线相比无显著差异。
  • 两组在角色生理和性功能量表均出现临床显著下降。
  • LDR-PB组在生理功能和泌尿功能量表上的平均评分下降显著大于DE-EBRT组。

研究设计与样本

  • 多中心随机试验,357例中高危前列腺癌患者按风险组分层后1:1随机。
  • DE-EBRT推量组177例,LDR-PB推量组180例,均为联合治疗的一部分。
  • 采用SF36v2问卷及泌尿、肠道、性功能附加量表评估HR-QoL,以开始雄激素剥夺治疗日期为时间零点,中位随访6年。
  • 量表评分0至100,平均评分较基线下降≥10定义为临床显著下降,采用意向性治疗分析。

主要发现

  • 基线时两组各领域平均评分均衡。
  • 两组角色生理平均评分较基线下降:DE-EBRT组-11.4,LDR-PB组-15.3。
  • 两组性功能平均评分较基线下降:DE-EBRT组-15.1,LDR-PB组-19.2。
  • LDR-PB组较DE-EBRT组生理功能平均评分下降更大(-15.3 vs -6.9;P=.03)。
  • LDR-PB组较DE-EBRT组泌尿功能平均评分下降更大(-3.6 vs -0.5;P=.04)。

临床怎么用

  • 为中高危前列腺癌患者选择剂量递增方式时,应告知LDR-PB推量相比DE-EBRT推量可能带来更明显的生理功能和泌尿功能评分下降。
  • 两组均需关注角色生理和性功能领域的临床显著下降,并在随访中评估相关生活质量影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the patient-reported health-related quality of life (HR-QoL) outcomes for a multicenter randomized trial evaluating the safety and efficacy of 2 different techniques for dose escalation. METHODS AND MATERIALS: A total of 357 men with intermediate- and high-risk prostate cancer were stratified by risk group and randomized (1:1) to either a dose-escalated external beam (DE-EBRT) boost (n=177) or a low-dose-rate prostate brachytherapy (LDR-PB) boost (n=180) as part of combined modality therapy. The HR-QoL was assessed using the SF36v2 questionnaire, with additional scales for urinary, bowel, and sexual function. Date of starting androgen deprivation therapy was considered time zero, the median follow-up of 6 years. Scales were scored from 0 to 100; a decline in a mean score ≥10 compared with baseline was considered a clinically significant decline. This was an intent-to-treat analysis. RESULTS: Mean domain scores at baseline were well balanced between the 2 treatment arms. A clinically significant decline in mean scores in both the arms compared with baseline was noted for role physical (DE-EBRT [-11.4] and LDR-PB [-15.3]) and sexual function scale (DE-EBRT [-15.1] and LDR-PB [-19.2]). There was a significantly larger drop in mean scores in the LDR-PB group compared with the DE-EBRT group for physical function (-15.3 vs -6.9; P=.03), urinary function (-3.6 vs -0.5; P=.04). CONCLUSION: At 6 years' follow up, there were no significant differences in mean scores in 9 of 11 scales compared with baseline in both arms. A clinically significant decline in mean scores was noted in both arms for role physical and sexual function scales. There was a statistically significant decline in physical function and urinary function scales in the LDR-PB arm compared with the DE-EBRT arm.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Rodda S, Morris WJ, Hamm J, et al. ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 28581398. doi:10.1016/j.ijrobp.2017.02.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。